Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

34.29 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
3 Growth Stocks That Could Rocket Higher in 2023
Upcoming binary events could push these stocks to new all-time highs. 
Via The Motley Fool
Newly Approved Drugs In US Command Over $200,000 On An Average
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003. 
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From uniQure Inc.
Via GlobeNewswire
Why UniQure Shares Are Plummeting Today?
 
Via Benzinga
UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial
 
Via Benzinga
Analyst Ratings for uniQure
Within the last quarter, uniQure (NASDAQ:QURE) has observed the following analyst ratings: 
Via Benzinga
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia B 
From uniQure Inc.
Via GlobeNewswire
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
From uniQure Inc.
Via GlobeNewswire
Why Shares of uniQure Rose 14.61% on Wednesday
A big approval for a gene therapy sent the biotech's stock higher. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Friday
  On Friday, 68 companies reached new 52-week highs. 
Via Benzinga
The FDA Just Approved The Most Expensive Drug Ever — Sending UniQure Stock On A Warpath
And shares of its developer are on a warpath this week. 
Via Investor's Business Daily
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
Via Benzinga
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
 
Via Benzinga
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
From uniQure Inc.
Via GlobeNewswire
uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022
From uniQure Inc.
Via GlobeNewswire
uniQure: Q3 Earnings Insights
uniQure (NASDAQ:QURE) reported its Q3 earnings results on Wednesday, November 2, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings uniQure beat estimated earnings by... 
Via Benzinga
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
Eight Posters Highlighting Pre-Clinical Programs and Leading Gene Therapy Manufacturing and Administration Capabilities 
From uniQure Inc.
Via GlobeNewswire
uniQure to Participate in Upcoming Industry Conferences in October
From uniQure Inc.
Via GlobeNewswire
Roblox's Stock Gets A Price Target Cut By This Analyst; Also Check Out Some Other Major PT Changes
Truist Securities boosted the price target on Roblox Corporation (NYSE: RBLX) from $29 to $45. However, Truist Securities analyst Matthew Thornton maintained the stock with a Hold. Roblox shares fell... 
Via Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. 
Via Benzinga
Nasdaq Turns Lower; Crude Oil Rises Over 1%
U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday. 
Via Benzinga
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6... 
Via Benzinga
Dow Jumps Over 150 Points; Karuna Therapeutics Shares Spike Higher
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday. 
Via Benzinga
Why U.S. Stocks Are Trading Higher; Tyson Foods Earnings Miss Views
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday. 
Via Benzinga
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating. 
Via Investor's Business Daily
Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data
The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time. 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
The Meaning Behind Value Stocks 
Via Benzinga
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.